Koninklijke Philips N.V. PHIA.AS
Composite 52/100; the shares have moved about 24% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 34/100 — a moderate mark against it.
Income ranks 73/100 — a moderate point in its favour. Growth ranks 63/100 — a moderate point in its favour. Valuation ranks 63/100 — a moderate point in its favour.
Momentum ranks 34/100 — a moderate mark against it. Balance-sheet strength ranks 46/100 — a slight mark against it. Quality ranks 48/100 — a slight mark against it.
What the company does Koninklijke Philips N.V. (PHIA.AS) is a Dutch health technology company focused on diagnostic imaging, image-guided therapy, connected care, and personal health solutions. It serves markets in North America, Greater China, and internationally, with offerings spanning MRI, CT, ultrasound, monitoring, and sleep/respiratory devices.
Key financials Revenue grew 0.5% while EPS surged 61.4%, reflecting margin expansion (gross 45.9%, operating 14.0%, net 6.3%). ROE stands at 10.2% and ROA at 4.1%, with debt/equity at 0.65 and net debt/EBITDA at 2.35. The dividend yield is 3.6% with a payout ratio of 74.6%.
Stock health Momentum is mixed: +5.75% over 3 months but -2.32% over 6 months, with a 12-month gain of 3.67% and RSI(14) at 42.90. The stock is -14.52% below its 52-week high, indicating some near-term pressure despite recent earnings.
Price vs fair value The stock trades at a **PREMIUM of 0.60%** to our fair-value estimate of 22.67 and a **discount of 20.26%** to the analyst 12-month target of 27.42. - Q2 earnings beat and raised guidance (Simply Wall St.) - Shares fell 9% despite strong sales growth due to weak orders (GuruFocus.com) - Tariff refunds provided partial relief but not a full recovery (MedTech Dive)
Looking forward Forward P/E of 15.08 and PEG of 0.31 suggest undemanding valuations, while growth (68.2 percentile) and income (77.2 percentile) pillars score well. Analysts see potential upside to 27.42, but near-term momentum and order trends remain key watchpoints.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.